Quick Answer
Elicio Therapeutics, Inc. reported Cash and Equivalents of $18.56 million for fiscal year 2025.
Elicio Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $18.56M | +5.4% |
| 2024 | $17.62M | +36.6% |
| 2023 | $12.89M | +109.5% |
| 2022 | $6.16M | -93.1% |
| 2021 | $88.76M | +156.5% |
| 2020 | $34.61M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.61M | -20.8% | -6.7% |
| June 30, 2025 | $22.09M | +544.9% | +20.4% |
| March 31, 2025 | $18.35M | +54.8% | +4.2% |
| December 31, 2024 | $17.62M | +36.6% | -32.3% |
| September 30, 2024 | $26.02M | +75.3% | +659.6% |
| June 30, 2024 | $3.42M | -84.2% | -71.1% |
| March 31, 2024 | $11.85M | +38.3% | -8.1% |
| December 31, 2023 | $12.89M | +109.5% | -13.1% |
- Elicio Therapeutics, Inc. showed an increase of +5.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Elicio Therapeutics, Inc.’s cash and equivalents has declined by 46.4% (from $34.61 million to $18.56 million).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: